This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

WFH guidelines



spontaneous bleeds



Refixia prophylaxis provides bleed free protection in children




(IQR: 0.00–0.98)**2

(IQR: 0.00–2.04)**2

(IQR: 0.00–4.00)**2

*With a 40 IU/kg once-weekly dose.7 As measured by ISTH target joint criteria at the end of paradigm4 clinical trial. The most recent definition of a target joint from the ISTH is ≥3 spontaneous bleeds into the joint within a consecutive 6-month period. When there have been ≤2 bleeds into the joint within a consecutive 12-month period, the joint is no longer considered a target joint.7 Patients had at least 150 exposure days to any FIX product prior to enrolment in the trial2

**Results from 29 patients (13–65 years) treated with 40 IU/kg once-weekly prophylaxis in the pivotal trial, paradigm22


ABR, annualised bleeding rate; IU, international unit; FIX, factor IX; IQR, interquartile range; ISTH, International Society on Thrombosis and Haemostasis

new target joint prevention for all patients 12 and under10

target joint resolution for children 7–1210

*Based on single-dose PK parameters of Refixia® 40 IU/kg15

**Mean steady-state pre-dose trough levels across the clinical trials for all previously treated children receiving Refixia® 40 IU/kg once weekly10,15

EHL, extended half-life; FIX, factor IX; IU, international unit; PK, pharmacokinetics; PTP, previously treated patient;
PUP, previously untreated patient


World Federation of Hemophilia (WFH). Guidelines for management of hemophilia, 3rd edition. Available at: (Accessed April 2022).




Collins PW et al. Blood 2014; 124:3880–3886.


Collins PW. Haemophilia 2012; 18:131–135.



Oldenburg J. Blood 2015; 125:2038–2044.


van Keep M et al. J Comp Eff Res 2018; 7:39–48.



iménez-Yuste V et al. Blood Transfus 2014; 12:314–319.


Negrier C et al. Haemophilia 2016; 22:507–513.



Lee A et al. Blood 2020; 136:37–38.



Matino D et al. Res Pract Thromb Haemost 2022; 6:e12661.



Refixia® Summary of Product Characteristics, 2023.


Tiede A et al. Haemophilia 2017; 23:547–555.


Young G et al. Thromb Res 2016; 141:69–76.


Castaman G. Expert Rev Hematol 2018; 11:673–683


Hansen JU et al. J Haem Pract 2022; 9:103–117


Carcao M et al. J Thromb Haemost 2016; 14:1521–1529


Chan AK et al. Res Pract Thromb Haemost 2020; 4:1101–1113.